Amgen beats the street and announces $425M cancer vaccine maker purchase
This article was originally published in Scrip
As the first drug maker out of the gate reporting 2010 year-end results, Amgen posted profits slightly better than Wall Street had been predicting in a year in which the company not only gained US approval of denosumab – the drug its banking its future on – but also won a second indication from the US FDA for the injectable RANK Ligand inhibitor.
You may also be interested in...
Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.